CHAE; Yu-Na

Patent Applications and Registrations

Patent applications and USPTO patent grants for CHAE; Yu-Na.The latest application filed is for "acylated oxyntomodulin peptide analog".

Company Profile

4.4.8

CHAE; Yu-Na - Yongin-si KR
Chae; Yu Na - Gyeonggi-do KR

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Acylated Oxyntomodulin Peptide Analog App 20220119473 - YANG; Jae-Sung ; et al.	2022-04-21
Pharmaceutical Composition For Preventing Or Treating Nonalcoholic Fatty Liver Disease, Containing Gpr119 Ligand As Active Ingredient App 20220047591 - Kim; Mi-Kyung ; et al.	2022-02-17
Acylated oxyntomodulin peptide analog Grant 11,236,142 - Yang , et al. February 1, 2	2022-02-01
Acylated Oxyntomodulin Peptide Analog App 20200354425 - YANG; Jae-Sung ; et al.	2020-11-12
Substituted piperidines having GPR119 agonistic activity Grant 10,428,055 - Yang , et al. October 1, 2	2019-10-01
Compound Having Gpr119 Agonistic Activity, Method For Preparing The Same, And Pharmaecutical Composition Including The Same As Effective Component App 20190092763 - Yang; Jae Sung ; et al.	2019-03-28
Pharmaceutical composition for prevention and treatment of diabetes or obesity comprising a compound that inhibits activity of dipeptidyl peptidase-IV, and other antidiabetic or antiobesity agents as active ingredients Grant 8,440,669 - Shin , et al. May 14, 2	2013-05-14
Pharmaceutical Composition For The Prevention Or The Treatment Of Non-alcoholic Fatty Liver Disease And The Method For Prevention Or Treatment Of Non-alcoholic Fatty Liver Disease Using The Same App 20130072459 - An; Gook-Jun ; et al.	2013-03-21
Pharmaceutical Composition for Prevention and Treatment of Diabetes or Obesity Comprising a Compound that Inhibits Activity of Dipeptidyl Peptidase-IV, and other Antidiabetic or Antiobesity Agents as Active Ingredients App 20110201624 - Shin; Chang Yell ; et al.	2011-08-18
Novel Phenylpropionic Acid Derivatives As Peroxisome Proliferator-activated Gamma Receptor Modulators, Method Of The Same, And Pharmaceutical Composition Comprising The Same App 20100063041 - Moon; Ho-Sang ; et al.	2010-03-11

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.